SK Bioscience to license vaccine technology to Colombia - The Korea Times

SK Bioscience to license vaccine technology to Colombia - The Korea Times

SK Bioscience signed a technology licensing agreement with Colombia's VECOL, including 600,000 doses of SKYVaricella ordered for 2026, backed by a $260M national vaccine localization program over 10 years. The deal signals a growing market for WHO-prequalified vaccine manufacturers willing to commit to in-country tech transfer — a model increasingly required for public health procurement across emerging markets.